RxDoctor Payments Data

Julia Motl, NP

Primary Care · Centereach, NYNPI 1538521455

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Tactile Systems Technology Inc accounts for 89.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $754 and has fallen 64.5% since, to $268 in 2025.

$2,406in general payments, 2019–2025

Across 87 payments — averaging $27.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tactile Systems Technology Inc$2K
  • Johnson & Johnson$92
  • Medtronic$53
  • 180 Medical, Inc.$51
  • Organogenesis Inc.$44
  • Terumo Medical Corporation$23

What the payments were for

  • Food & beverage$2,406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,406 in reported general payments places this provider in the 85th percentile of 239 primary care providers in New York.

See all primary care providers in New York

Medicare billing

Part B allowed, 2024
$14,977
Medicare patients
119
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$17,837
ClopidogrelClopidogrel Bisulfate20$242

Paid to pharmacies, not to this prescriber.

Other primary care in Centereach

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →